US Stock MarketDetailed Quotes

WW WW International

Watchlist

1.590
-0.070-4.22%

Close Apr 25 16:00 ET

1.620
+0.030+1.89%

Post 16:05 ET

125.94MMarket Cap-1089P/E (TTM)

WW International Stock Forum

Moomoo AI

Mar 15 19:42

No insider trading of WW International shares in the last quarter and low insider ownership compared to others leaves an unenthusiastic impression. Investors should note 3 warning signs for WW International.

WW International's Stock Sinks To US$1.87, But Insiders Sold Even Lower

Moomoo AI

Mar 14 23:30

Debbane's exit and Invus' stake sale in WW International seems well-timed considering the company's stock decline. The company's venture into remote prescription of weight-loss drugs via Sequence acquisition hasn't convinced investors of its resilience against GLP-1 drugs pressure.

This Investor Made Billions on Weight Watchers Over 23 Years and Got Out Just Before the Stock Imploded

Moomoo AI

Mar 6 20:15

The company's transition from self-restraint to medication for weight loss is seen as a necessary evolution, but the competitive landscape and supply constraints for GLP-1 drugs could pose challenges. As Oprah exits the stock, investors are advised to exercise caution.

WeightWatchers Is Seeking to Turn Its Business Around by Adding Subscribers to Its Clinical Business, Which Prescribes Medications Such as Ozempic and Zepbound -- Heard on the Street -- WSJ

Moomoo AI

Mar 1 23:07

Oprah Winfrey's departure has negatively impacted investor sentiment, causing a sharp drop in the company's stock. Her exit could potentially affect the company's future performance.

Oprah Winfrey Made $221 Million Selling Weight Watchers' Stock Over the Years

Moomoo AI

Feb 29 10:05

Winfrey's departure from the board and her decision to donate her shares could potentially impact the company's stock performance. The rising popularity of weight-loss drugs presents both opportunities and challenges for Weight Watchers and other companies in the industry.

Oprah's Departure From Weight Watchers' Board Is the Latest Bad News for the Stock, Amid Weight-loss-drug Frenzy

Moomoo AI

Feb 29 05:53

The company's revenue and digital subscribers have been declining over the last five years. The cash profitability has been mediocre and Q4 results were disappointing, falling short of Wall Street's expectations. The company's stock is down 22.8% on the results.

WW (NASDAQ:WW) Reports Q4 In Line With Expectations But Stock Drops 22.8%

Options Newsman

Feb 22 08:59

ColumnsOptions Market Statistics: Nvidia's Q4 Earnings Soar Beyond Forecasts, Fueled by Surging AI Demand

News Highlights
$NVIDIA(NVDA.US)$ shares fell by 2.85%, closing at $674.72. Its options trading volume is 1.55 million. Call contracts account for 60.9% of the total trading volume. The most traded calls are contracts of $1300 strike price that expire on Feb 23rd. The total volume reaches 56,084 with an open interest of 16,391. The most traded puts are contracts of a $600 strike price that expires o...

NVIDIA's Q4 Earnings Blowout: Buy, sell or hold?

Moomoo AI

Feb 22 03:39

Weight Watchers' stock suffers due to a controversial marketing campaign and increased competition. The acquisition of Sequence failed to sustain initial stock gains, hinting at strategic challenges.

Weight Watchers Weighed Down by Fallout From 'GLP-1 House' - Report

Moomoo AI

Jan 8 21:03

WW International's low P/S ratio indicates investor anticipation of restricted future growth due to poor revenue outlook, keeping its stock price's valuation low.

WW International, Inc.'s (NASDAQ:WW) Shares Lagging The Industry But So Is The Business

Moomoo AI

Dec 17, 2023 02:11

The GLP-1 Program is a strategic move following challenges with membership decline as GLP-1 drugs gained popularity. This shift and acquisition of Sequence could potentially help the company in reclaiming lapsed users according to Goldman Sachs analyst Jason English.

WeightWatchers Has a New $99 Monthly Plan - and It's Targeting Those on Drugs Like Ozempic and Wegovy

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall